Phase 2 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with Neovascular Age-related Macular Degeneration (a type of eye condition where abnormal blood vessels grow under the retina).
• People who are willing to sign a consent form agreeing to take part in the study.
• People who have already tried at least two standard eye injection treatments (Ranibizumab, Aflibercept, or Faricimab) without sufficient success, and are currently receiving these injections every 8 weeks or more frequently.
• People who are able to complete a required "wash-out period" (a waiting period after stopping their current eye injection) before joining — the length of this waiting period depends on which medication they are currently receiving (ranging from approximately 4 to 8 weeks depending on the drug).
• People whose eye scans show abnormal blood vessel activity in or near the central area of the retina, with signs such as fluid or abnormal tissue.
• People whose vision in the study eye falls within a specific range — roughly equivalent to being able to read between the 20/32 and 20/320 lines on a standard eye chart.
• People whose vision loss in the study eye is considered to be mainly caused by their retinal condition.
• People whose eye scans show the presence of fluid or certain structural changes in the central area of the retina.
• People whose liver, kidney, and blood test results are within an acceptable range (based on tests done within 7 days of starting treatment).

Who may not be able to join:

• People who have scarring, fibrous tissue, tissue wasting, or tears in the central part of the retina in the study eye.
• People with glaucoma (high pressure in the eye) that is not well controlled, even with medication (confirm with trial site).
• People with a history of a particular type of eye inflammation called uveitis that has no known cause or is linked to an immune system condition, in the study eye.
• People with a high degree of short-sightedness (at least 8 diopters) in the study eye, measured before any corrective eye surgery.
• People who have an active infection or inflammation around or outside the eye in either eye at the time of their initial assessment.
• People with high blood pressure that is not well controlled (specifically, a top reading above 160 or a bottom reading above 95).
• People currently taking steroid tablets (above a certain dose) or other medications that suppress the immune system for an ongoing condition.

Important: Always verify eligibility with the trial site directly before applying.